Lake Street Capital Markets Analyst, Ben Klieve, initiated coverage of Evogene Ltd. with a BUY rating and price target of $2 (EVGN-$2). Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
None of the information contained in this website constitutes a recommendation, solicitation or offer by Lake Street Capital Markets or its affiliates to buy or sell any securities, options or other financial instruments or provide any investment advice or service. Certain transactions give rise to substantial risk and are not suitable for all investors. Past performance does not guarantee future results.
920 Second Avenue South
Suite 700
Minneapolis, MN 55402
Copyright © 2020 Lake Street Capital Markets
